Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 4/2019

01.08.2019 | Systematic Review

Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis

verfasst von: Inger Marie Skoie, Ingvild Dalen, Roald Omdal

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Fatigue is frequent in patients with psoriasis. Though conventional drugs in general have no effect on fatigue, biological agents have demonstrated beneficial effects in several other chronic inflammatory diseases.

Objective

The objective of the present study was to evaluate the effect of biological drugs on fatigue in patients with psoriasis vulgaris.

Methods

We conducted a meta-analysis of randomized controlled trials in which anti-interleukin-12/23, anti-interleukin-23, anti-interleukin-17, or anti-tumor necrosis factor-α agents were used for psoriasis vulgaris and fatigue was an outcome measure.

Results

A total of eight randomized controlled trials fulfilled criteria for inclusion in the meta-analysis. The studies used two fatigue reporting scales: the Functional Assessment of Chronic Illness Therapy-Fatigue and the Short Form 36 Health Survey Vitality Subscale. Treatment by biological agents in general compared with placebo led to a significant reduction in fatigue, with a standardized mean difference of − 0.40 (95% confidence interval − 0.46 to − 0.34; p < 0.001).

Conclusion

Biological drugs used for the treatment of psoriasis vulgaris have a consistently small-to-moderate beneficial effect on fatigue independent of the type of drug.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095–6.PubMed
3.
Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–881.e1–30.CrossRef
4.
Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: integrating genetics and biology. J Investig Dermatol. 2010;130(5):1213–26.CrossRef
5.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.CrossRef
6.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.CrossRef
7.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.CrossRef
8.
Skoie IM, Dalen I, Ternowitz T, Jonsson G, Kvivik I, Norheim K, et al. Fatigue in psoriasis: a controlled study. Br J Dermatol. 2017;177(2):505–12.CrossRef
9.
Verhoeven EW, Kraaimaat FW, van de Kerkhof PC, van Weel C, Duller P, van der Valk PG, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol. 2007;156(6):1346–9.CrossRef
10.
Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996;9(6):456–60.CrossRef
11.
Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29(2):247–64.CrossRef
12.
Kent S, Bluthe RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ, et al. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA. 1992;89(19):9117–20.CrossRef
13.
Reinertsen KV, Grenaker Alnaes GI, Landmark-Hoyvik H, Loge JH, Wist E, Kristensen VN, et al. Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav Immun. 2011;25(7):1376–83.CrossRef
14.
Becker K, Kohen R, Lee R, Tanzi P, Zierath D, Cain K, et al. Poststroke fatigue: hints to a biological mechanism. J Stroke Cerebrovasc Dis. 2015;24(3):618–21.CrossRef
15.
Norheim KAA, Imgenberg-Kreuz J, Brun JG, Jonsson R, Ng WF, Theander E, Mandl T, Sivils KL, Rönnblom L, Nordmark G, Omdal R. Genetic determinants of fatigue in primary Sjögren’s syndrome: a genome wide association study. 2017 ACR/ARHP Annual Meeting, San Diego, CA. Arthritis Rheumatol. 2017;69(Suppl. 10):2017.
16.
Braekke Norheim K, Imgenberg-Kreuz J, Jonsdottir K, Janssen EA, Syvanen AC, Sandling JK, et al. Epigenome-wide DNA methylation patterns associated with fatigue in primary Sjogren’s syndrome. Rheumatology (Oxford). 2016;55(6):1074–82.CrossRef
17.
Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011;63(Suppl. 11):S263–86.CrossRef
18.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.CrossRef
19.
Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol. 2005;32(7):1261–6.PubMed
20.
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63–74.CrossRef
21.
Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–25.CrossRef
22.
Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol. 1995;22(4):639–43.PubMed
23.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRef
24.
Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;6:CD008334.
25.
Skoie IM, Ternowitz T, Jonsson G, Norheim K, Omdal R. Fatigue in psoriasis: a phenomenon to be explored. Br J Dermatol. 2015;172(5):1196–203.CrossRef
26.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;1(4):1.CrossRef
27.
Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a phase 3 study. J Eur Acad Dermatol Venereol. 2016;30(10):1753–9.CrossRef
28.
Higgins JPT, Green S, Cochrane C. Cochrane handbook for systematic reviews of interventions. S.l. London: The Cochrane Collaboration; 2011.
29.
Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162(1):137–46.CrossRef
30.
Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.CrossRef
31.
Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704–10.CrossRef
32.
Bradburn MJ, Deeks JJ, Altman DG. Metan: an alternative meta-analysis command. Stata Techn Bull. 1999;44:4–15.
33.
Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatol Treat. 2007;18(6):341–50.CrossRef
34.
Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatol Treat. 2007;18(1):25–31.CrossRef
35.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35.CrossRef
36.
Borenstein M. Introduction to meta-analysis. Chichester: Wiley; 2009.CrossRef
37.
Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161–8.CrossRef
38.
Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. Metan: fixed- and random-effects meta-analysis. Stata J. 2008;8(1):3–28.CrossRef
39.
Sullivan GM, Feinn R. Using effect size: or why the p value is not enough. J Grad Med Educ. 2012;4(3):279–82.CrossRef
40.
Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009;219(3):239–49.CrossRef
41.
Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153(6):1192–9.CrossRef
42.
Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2/3 trial. J Dermatol. 2012;39(9):761–9.CrossRef
43.
44.
Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52.CrossRef
45.
Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–9.CrossRef
46.
Jankovic S, Raznatovic M, Marinkovic J, Jankovic J, Kocev N, Tomic-Spiric V, et al. Health-related quality of life in patients with psoriasis. J Cutan Med Surg. 2011;15(1):29–36.CrossRef
47.
Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford). 2009;48(9):1077–82.CrossRef
48.
Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheumatol. 2005;53(5):697–702.CrossRef
49.
Norheim KB, Harboe E, Goransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren’s syndrome: a double blind, randomised clinical trial. PLoS One. 2012;7(1):e30123.CrossRef
50.
Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–15.CrossRef
51.
Bachelez H, Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–61.CrossRef
52.
Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–74.CrossRef
53.
Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606.CrossRef
54.
Reich KG, Foley P, Song M, Wasfi Y, Li S, Shen YK, Han C, Armstrong A. General health-related quality of life among plaque psoriasis patients treated with guselkumab or adalimumab: results from a phase 3 randomized clinical trial. In: 26th EADV Congress, 13–17 Sep 2017, Geneva.
Metadaten
Titel
Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis
verfasst von
Inger Marie Skoie
Ingvild Dalen
Roald Omdal
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2019
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-019-00434-w

Weitere Artikel der Ausgabe 4/2019

American Journal of Clinical Dermatology 4/2019 Zur Ausgabe

Leading Article

Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma

Book Review

Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends

Therapy in Practice

Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis

Review Article

Quality-of-Life Research in Acne Vulgaris: Current Status and Future Directions

Original Research Article

Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database

Therapy in Practice

Special Considerations in the Treatment of Mycosis Fungoides

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise